Mycosis fungoides

What is the long-term outlook for individuals with mycosis fungoides?

Mycosis fungoides (MF) has an indolent (low-grade) clinical course, which means that it may persist in one stage, or may slowly progress to another stage (from patches to thicker plaques and eventually to tumors) over years or sometimes decades. The condition is incurable in most affected individuals, with the exception of those with stage IA disease. The prognosis for each individual varies and is related to the disease stage at the time of diagnosis, the type and extent of skin lesions, and whether the disease is present in other areas of the body (extracutaneous).
Studies regarding the survival outcomes and prognosis have generally found that:

  • individuals with stage IA disease at the time od diagnosis who undergo treatment have a normal life expectancy (e.g. that expected based on age, sex and race) -- a 10-year survival rate of 97-98%.
  • individuals with stage IIB disease with cutaneous tumors have a median survival rate of 3.2 years (a 10-year survival rate of 42%).
  • those with stage III disease (generalized erythroderma) have a median survival rate of 4-6 years (a 10-year survival rate of 83%).
  • individuals with extracutaneous stage IVA (lymph nodes) or stage IVB (viscera) disease have a survival rate of less than 1.5 years (a 10-year survival rate of 20% for those with histologically documented lymph node involvement).
  • individuals with effaced lymph nodes, visceral involvement, and transformation to large T-cell lymphoma have an aggressive clinical course and usually die of systemic involvement or infections.

Other factors that may be associated with reduced survival and increased risk of disease progression include increased age, male sex, and increased lactate dehydrogenase (LDH).

Last updated on 05-01-20

Name: Cutaneous Lymphoma Foundation PO Box 374
Birmingham, MI, 48012, United States
Phone: +1-248-644-9014 Fax : +1-248-644-9014 Email: info@clfoundation.org Url: https://www.clfoundation.org/ Facebook: https://www.facebook.com/clfoundation

Note, these links are external searches against the National Laboratory of Medicine's drug database. You may need to adjust the search if there are no results found.

Drug Name Generic Name
Poteligeo mogamulizumab
Adcetris brentuximab vedotin

Connect with other users with Mycosis fungoides on the RareGuru app

Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!

The RareGuru disease database is regularly updated using data generously provided by GARD, the United States Genetic and Rare Disease Information Center.

People Using the App

Join the RareGuru Community

To connect, share, empower and heal today.

People Using the App